Home The Word Brain	My Amedeo FAQ Privacy About
	Chinese Coaching Already know some Chinese? Stay on track with structured, one-on-one coaching to make steady, long-term progress. By Meng Wu and BSK.

Lung Cancer

Free Subscription 05.01.2026 4 Am J Clin Oncol 2 Ann Oncol 5 Ann Surg Oncol 3 Ann Thorac Surg 6 Anticancer Res 10 BMC Cancer 1 Cancer 5 Cancer Res 2 Cancer Sci 1 Chest 2 Clin Lung Cancer 2 Eur J Cancer 2 Eur J Cardiothorac Surg 1 Genes Chromosomes Cancer 2 Int J Cancer 2 Int J Radiat Oncol Biol Phys 1 J Cancer Res Clin Oncol 1 J Natl Cancer Inst 1 J Nucl Med 4 J Thorac Cardiovasc Surg 2 J Thorac Oncol 1 JAMA Oncol 19 Lung Cancer 2 N Engl J Med 2 PLoS One 1 Proc Natl Acad Sci U S A

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Am J Clin Oncol

1. SHARMA A, Kandoi NM
   Integrating Genomic Data and Imaging in Lung Cancer Prediction Using a Hybrid Deep Learning Approach.
   Am J Clin Oncol. 2025 Dec 26. doi: 10.1097/COC.0000000000001288.
   PubMed         Abstract available
   
   
2. SHARMA A, Kandoi NM
   Accurate Lung Cancer Prediction From CT Scans Using Advanced Deep Learning Methods.
   Am J Clin Oncol. 2025 Dec 26. doi: 10.1097/COC.0000000000001286.
   PubMed         Abstract available
   
   
3. SHARMA A, Kandoi NM
   Deep Learning-Based Risk Factor Analysis for Accurate Prediction of Lung Cancer in High-Risk Populations.
   Am J Clin Oncol. 2025 Dec 24. doi: 10.1097/COC.0000000000001284.
   PubMed         Abstract available
   
   
4. LOTZ M, Keates S, Carr D, Noor N, et al
   Overactive Bladder Symptoms in Cancer Patients Undergoing Chemotherapy.
   Am J Clin Oncol. 2026;49:25-29.
   PubMed         Abstract available
   
   

   
   Ann Oncol

5. ZHENG MM, Xia Y, Pan K, Sun F, et al
   The evolving landscape of leptomeningeal metastases from NSCLC: an international, contemporary, multicenter cohort study.
   Ann Oncol. 2026;37:104-116.
   PubMed         Abstract available
   
   
6. FROST N, Joosten M, Franzen J, Wiesweg M, et al
   PET/CT-Guided Management of Immune Checkpoint Blockade and Post-Treatment Multi-Modal Profiling in Long-Term Responders with Metastatic Lung Cancer in the National Network Genomic Medicine Lung Cancer Germany (nNGM).
   Ann Oncol. 2025 Dec 30:S0923-7534(25)06329-X. doi: 10.1016/j.annonc.2025.
   PubMed         Abstract available
   
   

   
   Ann Surg Oncol

7. VAKOUFTSI AC, Antonopoulos C, Apostolou D, Vachlas K, et al
   Correction: Risk Factors for Recurrence of Non-Small-Cell Lung Cancer After Anatomical Segmentectomy.
   Ann Surg Oncol. 2025 Dec 27. doi: 10.1245/s10434-025-19006.
   PubMed        
   
   
8. YANG MZ, Gan W, Zhang LJ, Lin P, et al
   Prognostic Significance of the Uncertain Resection Based on the Extent of Nodal Dissection in Non-small-Cell Lung Cancer.
   Ann Surg Oncol. 2025 Dec 25. doi: 10.1245/s10434-025-18947.
   PubMed         Abstract available
   
   
9. MIMAE T
   Invited Editorial: Recurrence Risk Prediction in Lung Cancer.
   Ann Surg Oncol. 2025 Dec 25. doi: 10.1245/s10434-025-18936.
   PubMed        
   
   
10. WANG W, Zhu M
    Comment on Development and Validation of a Machine Learning-Based Predictive Model for Postoperative Frailty in Patients with Non-Small-Cell Lung Cancer and its Relation to Early Recovery.
    Ann Surg Oncol. 2025 Dec 25. doi: 10.1245/s10434-025-18635.
    PubMed        
    
    
11. WU Y, Xu H, Cheng X, Li P, et al
    Development and Validation of an Artificial Intelligence Surgical Video Analysis Model for Predicting Visceral Pleural Invasion in Lung Cancer Surgery: A Multicenter Study.
    Ann Surg Oncol. 2025 Dec 22. doi: 10.1245/s10434-025-18863.
    PubMed         Abstract available
    
    

    
    Ann Thorac Surg

12. BRANDT WS
    Synchronous Primary Lung Cancer: Sequence of Therapy and Tumor Biology.
    Ann Thorac Surg. 2025 Dec 31:S0003-4975(25)01282.
    PubMed        
    
    
13. LI X, Li Q, Zhao E, Yang F, et al
    Perioperative Outcomes of Robotic versus Video-Assisted Thoracoscopic Surgery in Non-Small Cell Lung Cancer After Neoadjuvant Therapy.
    Ann Thorac Surg. 2025 Dec 26:S0003-4975(25)01261.
    PubMed         Abstract available
    
    
14. KHAN AA, Shah SK, Adebayo OW, Brooks C, et al
    Association Between Surgical Start Time and Major Morbidity or Mortality after Pulmonary Resection.
    Ann Thorac Surg. 2025 May 28:S0003-4975(25)00446.
    PubMed         Abstract available
    
    

    
    Anticancer Res

15. SAIJO H, Hirohashi Y, Sumi T, Shijubo N, et al
    Tumor Stroma Infiltrating T Cells Predict the Efficacy of Anti-CTLA-4 Antibody in NSCLC.
    Anticancer Res. 2026;46:301-308.
    PubMed         Abstract available
    
    
16. UEDA K, Kawaguchi YO, Kataoka Y, Yoden M, et al
    Tumor-associated Neutrophils Promote Lung Cancer Growth and Metastasis via the Neutrophil Elastase.
    Anticancer Res. 2026;46:165-180.
    PubMed         Abstract available
    
    
17. YU E, Oike T, Sakai M, Tashiro M, et al
    Estimation of Tumor Control Probability of Carbon Ion Radiotherapy Using Cancer Type-specific Sensitivity Data.
    Anticancer Res. 2026;46:113-122.
    PubMed         Abstract available
    
    
18. KIM HB, Na YS, Kim SH, Lee HJ, et al
    Adenylate Kinase 2 Promotes Tumor Progression in Small-cell Lung Cancer via PI3K/AKT/mTOR Signaling.
    Anticancer Res. 2026;46:205-212.
    PubMed         Abstract available
    
    
19. NORIYAMA K, Todo N, Nakamura S, Tamiya N, et al
    Ginsenoside Rd Improves Anticancer Drug-induced Disturbance in Murine Airway Ciliary Motility.
    Anticancer Res. 2026;46:181-194.
    PubMed         Abstract available
    
    
20. TAMURA Y, Kawabata S, Yamaguchi R, Asai Y, et al
    TTF-1 Expression and Efficacy of Platinum and Pemetrexed Plus Pembrolizumab in Advanced Lung Adenocarcinoma.
    Anticancer Res. 2026;46:447-456.
    PubMed         Abstract available
    
    

    
    BMC Cancer

21. ZHANG M, Di Y, Liu Z, Yan M, et al
    IGFBP1 facilitates tumor proliferation, invasion and migration by modulating the MAPK-ERK signaling pathway in lung adenocarcinoma.
    BMC Cancer. 2025;25:1924.
    PubMed         Abstract available
    
    
22. HUANG P, Lin Z, Qiu Y, Chen D, et al
    Dual-layer spectral detector CT quantitative parameters and radiomics for predicting spread through air spaces of lung adenocarcinoma: a dual-center study.
    BMC Cancer. 2025;25:1905.
    PubMed         Abstract available
    
    
23. XU J, Zhu A, Xu Y, Zhang Y, et al
    Real-world analysis of subsequent-line strategies for EGFR C797S mutant non-small cell lung cancer patients acquired resistance to third-generation EGFR tyrosine kinase inhibitors.
    BMC Cancer. 2025;25:1879.
    PubMed         Abstract available
    
    
24. ALQASEM K, Alshwayyat S, Aljawabrah S, Maraqa K, et al
    Survival patterns and mutation profiles in never- and light-smokers with stage IV NSCLC.
    BMC Cancer. 2025;25:1906.
    PubMed         Abstract available
    
    
25. YANG J, Sun Y, Liang F, Shen Z, et al
    Network pharmacology analysis and in vitro experimental validation of liriodenine against non-small cell lung cancer.
    BMC Cancer. 2025 Dec 26. doi: 10.1186/s12885-025-15498.
    PubMed        
    
    
26. JIN K, Qu Y, Li S, Sun C, et al
    A survival prediction model for leptomeningeal metastasis patients with non-small cell lung cancer based on deep learning.
    BMC Cancer. 2025 Dec 28. doi: 10.1186/s12885-025-15503.
    PubMed        
    
    
27. WANG Z, Meng J, Liu G, Wang Y, et al
    Hepatotoxicity and efficacy associated with first- and new-generation EGFR-TKIs in patients with NSCLC: a systematic review and meta-analysis.
    BMC Cancer. 2025;25:1909.
    PubMed         Abstract available
    
    
28. LI R, Chen G, Shao Y, Jin X, et al
    Evaluating the value of circulating miR-21, miR-210 and miR-942 in the diagnosis of early-stage lung adenocarcinoma.
    BMC Cancer. 2025;25:1887.
    PubMed         Abstract available
    
    
29. AVASTHI KK, Manley BJ, Pellini B, Zhang J, et al
    Different plasma exosome isolation methods generated distinct microRNA and protein profiles in healthy controls and patients with advanced prostate and lung cancer.
    BMC Cancer. 2025 Dec 30. doi: 10.1186/s12885-025-15492.
    PubMed         Abstract available
    
    
30. WANG W, Xu X, Tian M, Han Q, et al
    Prognostic performance of the nutritional risk screening 2002 and the global leadership initiative on malnutrition in patients with lung cancer treated with immune checkpoint inhibitors.
    BMC Cancer. 2025;25:1893.
    PubMed         Abstract available
    
    

    
    Cancer

31. LOPICCOLO J, Tramontano AC, Florez N, Johnson BE, et al
    Patterns of lung cancer incidence in adults diagnosed under age 50 in the United States, 2000-2021.
    Cancer. 2026;132:e70217.
    PubMed         Abstract available
    
    

    
    Cancer Res

32. LIU P, Zheng J, Ma W, Lu J, et al
    Stress Promotes Lung Metastasis in Breast Cancer by Altering Neutrophil Differentiation.
    Cancer Res. 2025 Sep 24. doi: 10.1158/0008-5472.CAN-25-1763.
    PubMed         Abstract available
    
    
33. ASSIE JB, Meiller C, Stern E, Lasvergnas J, et al
    Pharmacogenomic Characterization of a Large Cohort of Patient-Derived Cell Lines Identifies Therapeutic Strategies for Pleural Mesothelioma.
    Cancer Res. 2026;86:196-212.
    PubMed         Abstract available
    
    
34. HULSE M, Wang M, Xu C, Carter J, et al
    PRT3789 Is a First-in-Human SMARCA2-Selective Degrader That Induces Synthetic Lethality in SMARCA4-Mutated Cancers.
    Cancer Res. 2026;86:213-235.
    PubMed         Abstract available
    
    
35. LASSE OPSAHL EL, Espinoza CE, Olivei AC, Okoye JO, et al
    Fibroblast STAT3 Activation Drives Organ-Specific Premetastatic Niche Formation.
    Cancer Res. 2026;86:22-39.
    PubMed         Abstract available
    
    
36. MUCCIOLO G, Biffi G
    Lung Metastases in Pancreatic Cancer: Timing Their First Breath.
    Cancer Res. 2026;86:7-9.
    PubMed         Abstract available
    
    

    
    Cancer Sci

37. SALEH MF, Nita A, Ohta Y, Kobayashi A, et al
    Hippo Pathway Drives Durable Non-Cell-Autonomous Ferroptosis Resistance in Lung Cancer.
    Cancer Sci. 2025 Dec 23. doi: 10.1111/cas.70299.
    PubMed         Abstract available
    
    
38. TANAKA F, Watanabe Y, Sugawara S, Okami J, et al
    Perioperative Nivolumab in Resectable Non-Small Cell Lung Cancer: A Subanalysis of Japanese Patients From Checkmate 77T.
    Cancer Sci. 2025 Dec 23. doi: 10.1111/cas.70300.
    PubMed         Abstract available
    
    

    
    Chest

39. VOLK RJ, Maki KG, Rogova A, Tu A, et al
    The Counseling and Shared Decision-Making Visit for Lung Cancer Screening: A Thematic Analysis of Public Comments to the Centers for Medicare & Medicaid Services during the 2021-2022 National Coverage Analysis Process.
    Chest. 2025 Dec 22:S0012-3692(25)05950-1. doi: 10.1016/j.chest.2025.
    PubMed         Abstract available
    
    

    
    Clin Lung Cancer

40. AGGARWAL C, Ng S, Kamalakar R, Beruti S, et al
    A United States-Based Real-World Study on Biomarker Testing and Rebiopsy Rates Among Patients With Non-Small Cell Lung Cancer Across Lines of Therapy.
    Clin Lung Cancer. 2025;27:82-91.
    PubMed         Abstract available
    
    
41. RIANO I, Velez MA, Pomares-Millan H, Blaquier J, et al
    Expanding Lung Cancer Clinical Trial Criteria: A Systematic Review on Inclusion of Patients with Brain Metastases and Leptomeningeal Disease.
    Clin Lung Cancer. 2025;27:92-98.
    PubMed         Abstract available
    
    

    
    Eur J Cancer

42. SINI C, Russo A, Cortinovis D, Muscarella LA, et al
    Braf-mutant metastatic non-small-cell lung cancer: Real world data from the Italian biomarker atlas database.
    Eur J Cancer. 2025;234:116191.
    PubMed         Abstract available
    
    
43. SYRIGOS KN, Bussell ME, Al-Shamsi HO, Khorshid O, et al
    Bridging the gap in lung cancer: A comprehensive global strategy for change.
    Eur J Cancer. 2025 Oct 25:116069. doi: 10.1016/j.ejca.2025.116069.
    PubMed         Abstract available
    
    

    
    Eur J Cardiothorac Surg

44. ACHILLEOS N, Schott I, Doerr F, Grapatsas K, et al
    Impact of lymph node metastasis patterns on long-term survival in upper lobe non-small cell lung cancer.
    Eur J Cardiothorac Surg. 2025 Dec 22:ezaf467. doi: 10.1093.
    PubMed         Abstract available
    
    
45. YUN T, Koo BJ, Na KJ, Lee S, et al
    Volumetric Compensation After Anatomical Lung Resection: Comparative Analysis of Lobectomy and Segmentectomy.
    Eur J Cardiothorac Surg. 2025;67:ezaf428.
    PubMed         Abstract available
    
    

    
    Genes Chromosomes Cancer

46. KHOZYAINOVA AA, Menyailo ME, Subrakova VG, Loos DM, et al
    Spatial Dynamics of Tumor Cell Plasticity in Lung Adenocarcinoma Revealed by Region-Specific Single Cell Transcriptomics.
    Genes Chromosomes Cancer. 2025;64:e70101.
    PubMed         Abstract available
    
    

    
    Int J Cancer

47. WU YL, Zhang L, Fan Y, Zhou J, et al
    Five-year outcomes of pembrolizumab versus chemotherapy in Chinese patients with non-small-cell lung cancer and programmed cell death ligand 1 tumor proportion score >/=1%: KEYNOTE-042 China study.
    Int J Cancer. 2025 Dec 31. doi: 10.1002/ijc.70265.
    PubMed         Abstract available
    
    
48. MAYURI M, Reddy Kandula S, Ramakrishna V, Sanka P, et al
    Cutting edge therapies: A review of Food and Drug Administration-approved drugs for non-small cell lung cancer.
    Int J Cancer. 2026 Jan 2. doi: 10.1002/ijc.70318.
    PubMed         Abstract available
    
    

    
    Int J Radiat Oncol Biol Phys

49. KOTHARI G, O'Byrne KJ, Brown C, Stockler MR, et al
    A Randomized Phase 2 Trial of Nivolumab and Stereotactic Ablative Body Radiotherapy (SABR) in Advanced Non-Small Cell Lung Cancer, Progressing After First- or Second-Line Chemotherapy (NIVORAD).
    Int J Radiat Oncol Biol Phys. 2025 Dec 19:S0360-3016(25)06610.
    PubMed         Abstract available
    
    
50. CAMMARERI E, Duijm M, Granton PV, Schillemans W, et al
    High dose REirradiation for in-field recurrent Lung Cancer in the THOrax (RETHO): outcomes of a phase 2 prospective clinical trial.
    Int J Radiat Oncol Biol Phys. 2025 Dec 20:S0360-3016(25)06616.
    PubMed         Abstract available
    
    

    
    J Cancer Res Clin Oncol

51. KUMAR RI, Jain K, Arora P, Gururajan H, et al
    Brahmi (Bacopa monnieri) plant preparation facilitates to enhance the activities of dendritic cells to control non-small cell lung cancer (NSCLC).
    J Cancer Res Clin Oncol. 2025;152:18.
    PubMed         Abstract available
    
    

    
    J Natl Cancer Inst

52. MANFUL A, Mercaldo S, Blume JD, Aldrich MC, et al
    Addressing algorithmic bias in lung cancer screening eligibility.
    J Natl Cancer Inst. 2025 Dec 29:djaf298. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    J Nucl Med

53. DING H, Li L, You D, Mou L, et al
    [(177)Lu]Lu-DOTATATE and [(177)Lu]Lu-DOTA-IBA Cocktail Therapy for Metastatic Small Cell Lung Cancer: Possible Applications in Clinical Practice.
    J Nucl Med. 2025 Dec 30:jnumed.125.271432. doi: 10.2967/jnumed.125.271432.
    PubMed        
    
    

    
    J Thorac Cardiovasc Surg

54. ARGENTO G, Rendina EA, D'Andrilli A, Ciccone AM, et al
    Replacement of the superior vena cava by the bovine pericardium conduit: Sustained patency without long-term anticoagulation.
    J Thorac Cardiovasc Surg. 2026;171:12-20.
    PubMed         Abstract available
    
    
55. WALSH LC, Rokah M, Seitlinger J, Gallina FT, et al
    VALUE Trial: Phase 1 safety and feasibility study of same-day discharge after video-assisted thoracoscopic surgery lung resection.
    J Thorac Cardiovasc Surg. 2026;171:33-39.
    PubMed         Abstract available
    
    
56. JONES DR, Opitz I, Harpole D, Yanagawa J, et al
    TROPION-Lung12: A phase 3 study of adjuvant datopotamab deruxtecan and rilvegostomig in ctDNA-positive or high-risk pathology stage I non-small cell lung cancer.
    J Thorac Cardiovasc Surg. 2026;171:1-9.
    PubMed         Abstract available
    
    
57. YANG Z, Mino-Kenudson M, Lanuti M, Jefferey Yang CF, et al
    Extent of Resection for STAS-positive Stage IA1-2 Non-Small Cell Lung Cancer.
    J Thorac Cardiovasc Surg. 2025 Dec 22:S0022-5223(25)01071.
    PubMed         Abstract available
    
    

    
    J Thorac Oncol

58. TANIMOTO A, Ramkumar K, Stewart CA, Zhang B, et al
    The impact of targeting TRAF2 and NCK-interacting protein kinase (TNIK) on anti-tumor effect and tumor immune environment in c-MYC-high small cell lung cancer.
    J Thorac Oncol. 2025 Dec 26:S1556-0864(25)03066.
    PubMed         Abstract available
    
    
59. PLANCHARD D, Kim HR, Suksombooncharoen T, Li R, et al
    Trastuzumab Deruxtecan in Patients with HER2-Overexpressing Non-Small Cell Lung Cancer: Results From Part 1 of the Open-label, Multicenter, Phase 1b DESTINY-Lung03 Trial.
    J Thorac Oncol. 2025 Dec 23:S1556-0864(25)03021.
    PubMed         Abstract available
    
    

    
    JAMA Oncol

60. KUKHAREVA PV, Li H, Balbin C, Stevens ER, et al
    Enhancement of Patient-Centered Lung Cancer Screening: The MyLungHealth Randomized Clinical Trial.
    JAMA Oncol. 2025 Dec 26:e255672. doi: 10.1001/jamaoncol.2025.5672.
    PubMed         Abstract available
    
    

    
    Lung Cancer

61. YOON DW, Shin S, Kim CH, Jeon YJ, et al
    Is sublobar resection a valid option for radiologically pure-solid clinical stage IA non-small cell lung cancer?: insights from real-world data and current status.
    Lung Cancer. 2025;212:108886.
    PubMed         Abstract available
    
    
62. JUNG HA, Lim J, Choi YL, Jeon YJ, et al
    The role of APOBEC in early-stage epidermal growth factor receptor-mutant non-small cell lung cancer.
    Lung Cancer. 2025;212:108892.
    PubMed         Abstract available
    
    
63. JONGBLOED M, Damhuis RAM, Van Geffen WH, de Boer P, et al
    Effect of treatment sequencing on outcome of patients with non-small cell lung cancer with a synchronous solitary extrathoracic metastasis.
    Lung Cancer. 2025;212:108889.
    PubMed         Abstract available
    
    
64. CHENG L, Wang D, Zhang X, Han B, et al
    Inavolisib for PIK3CA-mutant non-small cell lung cancer: A case report.
    Lung Cancer. 2025;212:108890.
    PubMed         Abstract available
    
    
65. SUPIOT R, Gherardi A, du Manoir de Juaye L, Doghri O, et al
    Cost-effectiveness of adjuvant alectinib in the treatment of patients with resected stage IB-IIIA ALK-positive non-small lung cancer in France, based on the ALINA study.
    Lung Cancer. 2026;211:108885.
    PubMed         Abstract available
    
    
66. HERNANDEZ S, Conde E, Alonso M, Curto D, et al
    Optimizing communication for ultrafast lung cancer biomarker testing: the UTOPIA pilot study.
    Lung Cancer. 2026;211:108887.
    PubMed         Abstract available
    
    
67. LU KH, Xiao Y, Akhtar A, Tapia J, et al
    Neighborhood matters: Predicting lung cancer screening adherence with explainable AI.
    Lung Cancer. 2026;211:108882.
    PubMed         Abstract available
    
    
68. KIM DK, Chong Y, Yeo MK, Kang DH, et al
    Multiomic analysis of treatment-naive NSCLC before the era of neoadjuvant immunotherapy reveals contrasting immune phenotypes in stage IIIA: node-dominant (T1N2) exhibiting hot versus tumor-dominant (T4N0) cold features.
    Lung Cancer. 2026;211:108879.
    PubMed         Abstract available
    
    
69. LI G, Liu C, Xi P, Hou L, et al
    Neoadjuvant immunotherapy plus chemotherapy in locally advanced stage III NSCLC patients undergoing definitive chemo-radiotherapy---a real?world multicenter retrospective study.
    Lung Cancer. 2026;211:108883.
    PubMed         Abstract available
    
    
70. AMBROSINI P, Berghmans T, Occhipinti M, Durieux V, et al
    Locoregional therapies in advanced and recurrent pleural mesothelioma: A systematic review.
    Lung Cancer. 2026;211:108877.
    PubMed         Abstract available
    
    
71. WANG D, Mu S, Zhang M, Tao G, et al
    A pathomics model for predicting response to chemo-immunotherapy in lung squamous cell carcinoma: A multicenter study.
    Lung Cancer. 2026;211:108881.
    PubMed         Abstract available
    
    
72. MENDONCA L, Onwuka S, York S, Martinez-Gutierrez J, et al
    Identifying eligible patients for the Australian national lung cancer screening program in primary care: A cross-sectional study using clinical decision support systems and evaluating PLCO(m2012) data quality.
    Lung Cancer. 2026;211:108880.
    PubMed         Abstract available
    
    
73. FU L, Liu K, Liu Y, Gao Y, et al
    Global patterns and trends in mesothelioma incidence: A retrospective cross-sectional study.
    Lung Cancer. 2026;211:108878.
    PubMed         Abstract available
    
    
74. WU JY, Liang GZ, Chen TQ, Qiu HP, et al
    Prognostic comparison of lymph node metastasis subtypes in lung adenocarcinoma: clinical implications of intranodal metastasis versus extranodal extension for optimizing R classification.
    Lung Cancer. 2026;211:108876.
    PubMed         Abstract available
    
    
75. ZHANG B, Alder L, Rosner S, Desai A, et al
    A multi-institutional perspective on tarlatamab administration and management of CRS/ICANS.
    Lung Cancer. 2026;211:108870.
    PubMed         Abstract available
    
    
76. ALEXANDER M, Itchins M, Felthun J, Nagrial A, et al
    Impact of PD-L1 on first-line osimertinib outcomes in EGFR-mutant NSCLC: real-world data from the AURORA25 study and meta-analysis.
    Lung Cancer. 2026;211:108854.
    PubMed         Abstract available
    
    
77. TANG Y, Du W, Zhang X, Yang X, et al
    Long-term survival with PD-1/PD-L1 inhibitors plus platinum-based chemotherapy versus chemotherapy alone in locally advanced or metastatic pulmonary lymphoepithelioma-like carcinoma: updated follow-up analysis.
    Lung Cancer. 2026;211:108855.
    PubMed         Abstract available
    
    
78. BOWEN JONES S, Hayton C, Lodhi A, Umar A, et al
    Radiotherapy outcomes in patients with interstitial lung disease and interstitial lung abnormalities: Adverse events and survival from a UK tertiary centre.
    Lung Cancer. 2026;211:108873.
    PubMed         Abstract available
    
    
79. SINDI IA, Abu-Elsaoud AM, Almars AI, Ghouth NM, et al
    KRAS(G12D/G13D)-USP15 axis promotes TGF-beta/SMAD signaling and glycolytic flux to accelerate NSCLC pathogenesis.
    Lung Cancer. 2026;211:108848.
    PubMed         Abstract available
    
    

    
    N Engl J Med

80. FANG W, Wu L, Meng X, Yao Y, et al
    Sacituzumab Tirumotecan in EGFR-TKI-Resistant, EGFR-Mutated Advanced NSCLC.
    N Engl J Med. 2026;394:13-26.
    PubMed         Abstract available
    
    
81. JANNE PA, Planchard D, Kobayashi K, Yang JC, et al
    Survival with Osimertinib plus Chemotherapy in EGFR-Mutated Advanced NSCLC.
    N Engl J Med. 2026;394:27-38.
    PubMed         Abstract available
    
    

    
    PLoS One

82. ZHANG Z, Lin Z, Li W, Chen B, et al
    Sestrin3 confers resistance to recombinant human arginase in small cell lung cancer by activating Akt/mTOR/ASS1 axis.
    PLoS One. 2025;20:e0338802.
    PubMed         Abstract available
    
    
83. TANG L, Chen Y, Zhan S, Zhu L, et al
    Socazolimab combined with carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer: A cost-effectiveness analysis in China.
    PLoS One. 2025;20:e0339663.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

84. IMPHENG H, Gillard G, Numnoi N, Feral A, et al
    Peptide-based covalent inhibitor of tubulin detyrosination promotes mesenchymal-to-epithelial transition in lung cancer cells.
    Proc Natl Acad Sci U S A. 2026;123:e2514990123.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.